title: One-year clinical outcomes after sirolimus-eluting coronary stent implantation for acute myocardial infarction in the worldwide e-SELECT registry.
abstract: BACKGROUND
  The aim was to ascertain the 1-year clinical outcomes of 1,234 patients who underwent implantations of sirolimus-eluting stents (SES) for acute myocardial infarction (MI) in the multinational e-SELECT registry.
  
  
  METHODS
  Fifteen thousand and one hundred and forty-seven patients treated with SES were entered in the e-SELECT registry, of whom 1,234 presented within <24 hours of onset of acute MI.
  
  
  RESULTS
  At 1 year, the rates of major adverse cardiac events (MACE) (5.5% vs. 4.8%; P = 0.28) were similarly low in the acute and no acute MI groups. The rates of definite/probable stent thrombosis (ST) were higher in the acute MI group (2.1%vs; 0.88%, P < 0.001). ST was a strong independent predictor of death at 1 year (HR 13.4; 95% CI 5.0, 36.0; P < 0.001) and MI (HR 58.9; 95% CI 26.9, 129.1; P < 0.001). Dual antiplatelet therapy (DAPT) compliance at 6 months was 96.0% in the acute MI versus 94.5% in the no acute MI group (P = 0.03).
  
  
  CONCLUSIONS
  In selected patients presenting within <24 hours of acute MI onset and highly compliant with DAPT, SES implantation was associated with similar rates of MACE, though higher rates of ST, as compared to no acute MI patients.
authors.affiliation: Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, Australia.
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Worthley
authors.forename: Alexandre
authors.initials: A
authors.lastname: Abizaid
authors.forename: Adrian
authors.initials: A
authors.lastname: Banning
authors.forename: Antonio
authors.initials: A
authors.lastname: Bartorelli
authors.forename: Vladimír
authors.initials: V
authors.lastname: Džavík
authors.forename: Stephen
authors.initials: S
authors.lastname: Ellis
authors.forename: Runlin
authors.initials: R
authors.lastname: Gao
authors.forename: Victor
authors.initials: V
authors.lastname: Legrand
authors.forename: Philip
authors.initials: P
authors.lastname: Urban
authors.forename: Christian
authors.initials: C
authors.lastname: Spaulding
mesh_terms: D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000628:therapy*; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000517:prevention & control*; D012042:Registries; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D020123:Sirolimus